1Silver MA, Maisel A, Yaney CW, et al. B BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases [ J]. Congest Heart Fail, 2004,10 (5 Suppl 3) :1 -30.
2Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of Btype natrl uretic peptide in the emergency diagnosis of heart failure [ J]. N Engl J Meal,2002,347 (3) : 161 - 167.
3Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide(BNP) predicts future cardiac events in patients presenting to the emergency department with dypnea[J]. Ann of Emerg Med,2002,39:131 - 138.
4Emily Lubien , Anthony, DeMafia, et al. Utility of B - natriuretie peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings [ J 1. Circulation ,2002,105:595 - 601.
1Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature, 1988, 332:78-81.
2Mukoyama M, Nakao K, Saito Y, et al. Increased huan brain natriuretic peptide in congestive heart failure. N Engl J Med, 1990,323:757-758.
3Morrison KL,Harrison A,Krishnaswany P,et al. Vtility of a rapid B-natriuretic peptide (BNP) assay in differentiating CHF from lung disease in patients presenting with dyspnea. J Am Coll Cardiol,2002, 39:202-209.
4Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic poptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J, 2001, 141:367-374.
5Joung BY, Park BE, Kim DS, et al. B-type Natriuretic peptide predicts clinical presentations and ventricular overloading in patients with Heart Failure. Yonsei Medical J, 2003, 44:623-634.
6Groenning BA, Nilsson JC, Sondergaavd L, et al. Evaluation of impaired left ventficular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. European Journal of Heart Failure, 2001,3:699-708.
7McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet, 1998,351 :9-13.
8Ry SD, Clerico A, Giannessi D, et al. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an immunoradiometric assay method. Scand J Clin Lab Invest, 2000, 60 : 81-90.
9Fonseca C, Sarmento PM, Minez A ,et al. Comparative value of BNP and NT-proBNP in diagnosis of heart failure. Rev Port Cardiol,2004, 23:979-91.
10de Bold A J, Bnmeau BG, de Bold MLK. Mechanical and neurocndocrine regulation of the endocrine heart. Cariovasc Res,1996, 31:7-18.
2DICKSTEIN K. Natriuretic peptides in detection of heart failure. Lancet, 1997,351 : 3.
3Luchnera, Stevenstl, Borgeson DD, et al.Different atrial and ventricular expression of myocardial BNP during evolution of heart failure.Am J Physiol, 1998,274 : 1684.
4Sabatine MS,Morrow DA,de Lemos JA,et al. Elevation of B-type natriuretic peptide in the setting of myocardial ischemia.Circulation, 2001,104(Suppl 1/) : 485.
5DeLemosJA,Morrow DA,Bentley JH,et al.The prognostic value of B-type natriuretie peptide in patientswith acute coronary syndromes. N Engl J Med,2001,345 : 1014.
6Watanabe S,Shite J,Takaoka H,et al.Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure. Eur Heart J ,2006,27 : 832.
